Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease.

ABSTRACT:

Background and aims

Excessive alcohol consumption poses a significant global health concern, ranking as the world's third-largest risk factor for diseases and disabilities, contributing to 5.9% of all deaths worldwide. Among various disorders linked to alcohol misuse, alcohol-associated liver disease (ALD) is the most prominent. ALD patients often exhibit increased intestinal permeability, systemic inflammation, gut dysbiosis, and hepatic steatosis. No FDA-approved therapies are available to treat ALD or to resolve the pathological domains of alcohol-induced gut barrier dysfunction, inflammation, and steatosis. The goal of this study is to investigate the potential therapeutic role of the microbial metabolite Urolithin A' (UroA), in alleviating ALD.

Methods

Caco-2 (monolayer

SUBMITTER: Ghosh S 

PROVIDER: S-EPMC12862256 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature